If Gilead’s investors are worried the company’s new leadership team won’t pony up to support key launches—starting with HIV drug Descovy in PrEP—they don’t need to be, according to CEO Daniel O’Day. Historically, “at times of important launches” Gilead’s investment has “increased correspondingly,” and that will continue, he noted on the company’s Q3 call.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
